TREATMENT
Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer — Clinical Colorectal Cancer
A case report from the AGMT mCRC Registry documented successful encorafenib and cetuximab re-challenge combined with nivolumab in BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer.
If you have BRAF V600E-mutated colorectal cancer that previously responded to targeted therapy, this case suggests that re-treatment with the same combination plus immunotherapy may be worth discussing with your care team.